集体诉讼通知 - 股东在2023年2月16日至2025年2月12日期间购买West Pharmaceutical Services Inc (NYSE: WST)股票可参与集体诉讼 注册截止日期为2025年7月7日 [3][4] - 诉讼指控公司在上述期间发布 materially false and/or misleading statements 或未披露重大信息 导致股价被人为抬高 [3] 公司具体指控 - 公司声称对客户需求有 strong visibility 并将阻力归因于 temporary COVID-related product destocking 但实际上其高利润率HVP产品组合正经历 significant and ongoing destocking [3] - 公司主打的高利润率增长产品SmartDose设备因 operational inefficiencies 严重稀释了整体利润 margins [3] - 上述利润率压力导致公司面临 costly restructuring activities 包括退出与长期客户的 continuous glucose monitoring contracts [3] 律所信息 - The Gross Law Firm为全美知名集体诉讼律所 专注于因 deceit fraud and illegal business practices 受损的投资者权益保护 [5] - 律所通过 portfolio monitoring software 为注册股东提供案件进展更新 参与诉讼无需费用 [4][5]

IQVIA股票分析 Adhishthana周期现状 - IQVIA目前处于18阶段Adhishthana周期的第18阶段 表面看可能准备新动向 但多时间框架分析显示其陷入可能持续至2030年的时间螺旋[1] - 该周期始于2013年5月6日 前17阶段与Adhishthana原则保持88.88%的高吻合度 该原则是结合周期分析、量化信号和行为模式的专有框架[2] 关键价格水平与形态 - 第6阶段形成"涅槃水平"101.885美元 该水平成为长期估值基准和极端熊市时的磁吸位 近期股价在此反弹验证其重要性[4] - 第4至8阶段构建经典看涨通道"Cakra" 但第9阶段未突破反而跌破通道 引发瀑布式下跌 最终在涅槃水平获得支撑[7] - 类似Cakra破位现象近期也出现在Regeneron制药公司[8] 周期异常与失效信号 - 第10-11阶段本应是上升期 但早期Cakra破位使看涨形态失效 股价已持续1200多天处于熊市控制[8] - 第14-16阶段未能形成看涨能量"Satoguna" 第15阶段虽有微弱上涨但缺乏力度 导致第18阶段达到峰值的可能性低[11] 长期时间框架分析 - 月线图显示处于第3阶段"Yajya形态" 解释其长期下跌趋势 该阶段持续至2026年11月1日[16] - 随后将进入第4阶段"无为期" 持续至2030年4月30日 此期间无论价格如何波动都应保持观望[14][16] 投资者策略提示 - 需保持耐心 不适合短线操作 尽管股价从历史高点下跌超50% 但受困于时间螺旋 短期内难有快速回报[15]

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by ...

West Pharmaceutical Services (WST) closed the last trading session at $223.77, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $284 indicates a 26.9% upside potential.The average comprises 10 short-term price targets ranging from a low of $245 to a high of $355, with a standard deviation of $34.94. While the lowest estimate indicates an increase of 9.5% from the current ...

诉讼案件概述 - Levi & Korsinsky律师事务所针对West Pharmaceutical Services Inc (NYSE: WST)发起证券集体诉讼 [1] - 诉讼旨在为2023年2月16日至2025年2月12日期间因涉嫌证券欺诈遭受损失的投资者追偿损失 [2] 指控内容 - 公司被指控虚假陈述或隐瞒事实：尽管声称对客户需求有清晰可见性并将阻力归因于临时性COVID相关产品去库存化，但实际上其高利润率HVP产品组合正经历持续重大去库存化 [3] - SmartDose设备虽被定位为高利润率增长产品，但因运营效率低下严重稀释公司整体利润率 [3] - 利润率压力导致公司可能退出与长期客户的连续血糖监测合同等成本高昂的重组活动 [3] - 公司关于业务运营和前景的积极陈述因此存在重大虚假或误导性 [3] 诉讼程序 - 受影响投资者需在2025年7月7日前申请成为首席原告 [4] - 集体成员可能无需支付自付费用即可获得赔偿 [4] 律所背景 - Levi & Korsinsky过去20年为受损股东追回数亿美元，拥有70多名员工的团队专门处理复杂证券诉讼 [5] - 连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼律所之一 [5]

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...

诉讼案件概述 - Levi & Korsinsky律师事务所针对West Pharmaceutical Services Inc (NYSE: WST)发起证券集体诉讼 旨在为2023年2月16日至2025年2月12日期间因涉嫌证券欺诈遭受损失的投资者追偿损失 [1][2] - 诉讼截止日期为2025年7月7日 符合条件的投资者可申请成为首席原告 但参与赔偿无需承担任何费用 [4] 指控内容 - 公司被指控虚假陈述和隐瞒事实 包括将业绩下滑归因于临时性COVID相关产品去库存 而实际上其高利润HVP产品组合持续面临显著去库存压力 [3] - 公司宣称高利润增长产品SmartDose设备 由于运营效率低下 实际严重稀释了整体利润率 [3] - 利润率压力导致公司可能退出与长期客户的连续血糖监测合同 并面临高成本重组活动 [3] - 基于上述情况 公司关于业务运营和前景的正面陈述被指控存在重大虚假或误导性 [3] 律所背景 - Levi & Korsinsky过去20年累计为受损股东追回数亿美元赔偿 在复杂证券诉讼领域具有专业经验 [5] - 该律所连续7年被ISS证券集体诉讼服务评为全美前50大证券诉讼律所之一 拥有70多名专业人员团队 [5]

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=150517&fro ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) --  Faruqi & ...